A review and recommendations on the management of psoriatic arthritis in Australia 2024

被引：0
作者：
Nash, Peter [1 ,2 ,3 ]
Sumpton, Daniel [4 ]
Tellus, Michelle [5 ]
Feletar, Marie [6 ]
Bird, Paul [6 ]
Hall, Stephen [7 ,8 ]
机构：
[1] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[2] Rheumatol Res Unit, Sunshine Coast, Qld, Australia
[3] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[4] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[5] St Vincents Private Hosp, Melbourne, Vic, Australia
[6] Univ New South Wales, Sch Clin Med, Sydney, NSW, Australia
[7] Cabrini Hosp, Melbourne Rheumatol, Melbourne, Vic, Australia
[8] Monash Univ, Monash, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2024年 / 54卷 / 12期
关键词：
psoriatic arthritis; psoriatic arthritis drug therapy; pharmacotherapy; Australia; PLACEBO-CONTROLLED TRIAL; ACTIVE ANKYLOSING-SPONDYLITIS; DOUBLE-BLIND; EULAR RECOMMENDATIONS; MONOCLONAL-ANTIBODY; CERTOLIZUMAB PEGOL; PLACENTAL-TRANSFER; PRESCRIBING DRUGS; SACROILIAC JOINT; BHPR GUIDELINE;
D O I：
10.1111/imj.16557
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Psoriatic arthritis (PsA) is a progressive, systemic inflammatory disease. It can lead to serious joint damage and disability, increased cardiovascular risk and reduced quality of life. Six experts met to develop the recommendations for the management of PsA in Australia. The final recommendations are approved by all panel members. Management and treatment recommendations have been made under six subheadings: Recommendations for non-steroidal anti-inflammatory drugs and glucocorticoids; Disease-modifying treatment; Screening and monitoring; Family planning; Symptom treatment and extra-articular manifestations; Comorbidities and lifestyle considerations. Our recommendations for the management of PsA in Australia draw heavily on the established global guidelines. These recommendations aim to assist clinicians to make informed, patient-centric choices when delivering treatment to people with PsA.
引用
收藏
页码：2037 / 2053
页数：17
相关论文
共 129 条
[1]   Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates [J].
Alnaqbi, Khalid A. ;
Hannawi, Suad ;
Namas, Rajaie ;
Alshehhi, Waleed ;
Badsha, Humeira ;
Al-Saleh, Jamal .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (10) :1107-1122
[2]   Consensus statements for evaluation and nonpharmacological Management of Psoriatic Arthritis in UAE [J].
Alnaqbi, Khalid A. ;
Hannawi, Saud ;
Namas, Rajaie ;
Alshehhi, Waleed ;
Badsha, Humeira ;
Al-Saleh, Jamal .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2022, 25 (07) :725-732
[3]   Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study [J].
Araujo, Elizabeth G. ;
Englbrecht, Matthias ;
Hoepken, Sabrina ;
Finzel, Stephanie ;
Kampylafka, Eleni ;
Kleyer, Arnd ;
Bayat, Sarah ;
Schoenau, Verena ;
Hueber, Axel ;
Rech, Juergen ;
Schett, Georg .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (04) :632-637
[4]  
Australian Rheumatology Association, 2023, BIOL TARGETED SYNTHE
[5]  
Australian Rheumatology Association, 2023, PRESCRIBERS INFORM M
[6]   Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis [J].
Baeten, Dominique ;
Sieper, Joachim ;
Braun, Juergen ;
Baraliakos, Xenofon ;
Dougados, Maxime ;
Emery, Paul ;
Deodhar, Atul ;
Porter, Brian ;
Martin, Ruvie ;
Andersson, Mats ;
Mpofu, Shephard ;
Richards, Hanno B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2534-2548
[7]   Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies [J].
Baraliakos, Xenofon ;
Ranza, Roberto ;
Ostor, Andrew ;
Ciccia, Francesco ;
Coates, Laura C. ;
Rednic, Simona ;
Walsh, Jessica A. ;
Douglas, Kevin ;
Gao, Tianming ;
Kato, Koji ;
Song, In-Ho ;
Ganz, Fabiana ;
Deodhar, Atul .
ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
[8]   Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial [J].
Baraliakos, Xenofon ;
Gossec, Laure ;
Pournara, Effie ;
Jeka, Slawomir ;
Mera-Varela, Antonio ;
D'Angelo, Salvatore ;
Schulz, Barbara ;
Rissler, Michael ;
Nagar, Kriti ;
Perella, Chiara ;
Coates, Laura C. .
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) :582-590
[9]   Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study [J].
Baranauskaite, Asta ;
Raffayova, Helena ;
Kungurov, N. V. ;
Kubanova, Anna ;
Venalis, Algirdas ;
Helmle, Laszlo ;
Srinivasan, Shankar ;
Nasonov, Evgeny ;
Vastesaeger, Nathan .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (04) :541-548
[10]   Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk [J].
Barbarroja, Nuria ;
Ruiz-Ponce, Miriam ;
Cuesta-Lopez, Laura ;
Perez-Sanchez, Carlos ;
Lopez-Pedrera, Chary ;
Arias-de La Rosa, Ivan ;
Collantes-Estevez, Eduardo .
FRONTIERS IN IMMUNOLOGY, 2022, 13
12345678910